KIT and gastrointestinal stromal tumor: In GIST, regorafenib has demonstrated sustained benefits for patients harboring secondary KIT mutations associated with imatinib or sunitinib resistance, with continued research focusing on optimizing sequencing strategies among KIT-targeted TKIs [123].